Company
ADmit THERAPEUTICS
- AI
- Biotech
- Headquarters:
- Barcelona, Spain
- Offices:
- Sant Feliu de Llobregat, Spain
Description
ADmit THERAPEUTICS develops and commercializes an IVDR CE‑marked blood-based prognostic test (MAP‑AD®) that uses mitochondrial DNA methylation, next‑generation sequencing, and machine learning to predict progression to Alzheimer’s dementia from mild cognitive impairment.
ADmit THERAPEUTICS is located in the Barcelona ecosystem.
Related
AbridgeAbridge builds an AI assistant that turns clinical conversations into draft and billable documentation for clinicians, nursing teams, and…
Adaptive Biotechnologies ($ADPT)Adaptive Biotechnologies develops immune-system-based diagnostics and data tools, including NGS MRD testing, for clinicians and biopharma…
Age LabsAge Labs develops epigenetic biomarkers and predictive algorithms for early detection of age-related diseases and drug response, providing…
Ångström AIÅngström AI develops diagnostics using amplicon sequencing and machine learning, aiming to broaden access to sequencing-based diagnostic…
APCAPC builds accelerated drug process development services and technologies for small and large pharmaceutical and biotech companies,…
Archangel HealthArchangel Health provide infrastructure software that powers medical artificial intelligence systems, helping healthcare teams operate…
AsimovAsimov designs and delivers integrated cells, genetic constructs, and cloud software to enable commercial-grade cell line and viral vector…
Atlas DiscoveryAtlas Discovery builds autonomous agents to find new disease uses for existing drugs, support more efficient clinical trials, and present…
Atomic AIAtomic AI develops machine-learning and structural-biology tools for RNA drug discovery, supporting RNA-targeted small molecules, RNA-based…